In our comprehensive analysis, we integrated multiple analytical methods to evaluate the potential effectiveness of CCR8 and immune checkpoint inhibitor (ICI) combination therapy across six selected cancer types (Table 5). The gene discussed is CCR8; the disease is cancer.